Spots Global Cancer Trial Database for secondary myelodysplastic syndrome

Every month we try and update this database with for secondary myelodysplastic syndrome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia	NCT00357565	Leukemia Myelodysplastic... Childhood Acute... Recurrent Child... Secondary Acute... Childhood Acute... Previously Trea... Secondary Myelo... Refractory Anem... Refractory Anem... Refractory Anem... De Novo Myelody... Childhood Myelo...	filgrastim busulfan cyclosporine fludarabine pho... melphalan mycophenolate m... umbilical cord ...	- 3 Years	Masonic Cancer Center, University of Minnesota
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome	NCT02553941	Chronic Myelomo... de Novo Myelody... Previously Trea... Refractory Anem... Secondary Myelo...	Azacitidine Ibrutinib	18 Years -	University of California, Davis
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders	NCT00588991	Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Chronic Myeloid... Chronic Myelomo... de Novo Myelody... Essential Throm... Hematopoietic a... Myelodysplastic... Polycythemia Ve... Recurrent Adult... Recurrent Adult... Secondary Myelo...	Carboplatin Laboratory Biom... Topotecan Hydro... Veliparib	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	NCT00217646	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Blastic Phase de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Secondary Acute... Secondary Myelo...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant	NCT02485535	Acute Myeloid L... de Novo Myelody... Myelodysplastic... Secondary Acute... Secondary Myelo...	Laboratory Biom... Selinexor	-	University of Chicago
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia	NCT01168219	Acute Myeloid L... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... de Novo Myelody... Myelodysplastic... Myelodysplastic... Recurrent Adult... Secondary Myelo...	Allogeneic Hema... Anti-Thymocyte ... Azacitidine Busulfan Fludarabine Pho... Laboratory Biom... Methotrexate Pharmacological... Tacrolimus	18 Years - 74 Years	National Cancer Institute (NCI)
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	NCT02890329	Previously Trea... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... Secondary Acute... Secondary Myelo...	Decitabine Ipilimumab	18 Years -	National Cancer Institute (NCI)
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia	NCT01885689	Adult Acute Lym... Acute Myeloid L... Adult Acute Mye... Myelodysplastic... Secondary Myelo... Chronic Myelomo... Therapy-Related...	clofarabine melphalan allogeneic hema... tacrolimus sirolimus Pharmacological...	18 Years - 75 Years	City of Hope Medical Center
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	NCT00217646	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Blastic Phase de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Secondary Acute... Secondary Myelo...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	NCT00313586	Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Alkylating Agen... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult...	Azacitidine Entinostat Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia	NCT01757639	Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Previously Trea... Recurrent Adult... Secondary Myelo...	Ipilimumab Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia	NCT01885689	Adult Acute Lym... Acute Myeloid L... Adult Acute Mye... Myelodysplastic... Secondary Myelo... Chronic Myelomo... Therapy-Related...	clofarabine melphalan allogeneic hema... tacrolimus sirolimus Pharmacological...	18 Years - 75 Years	City of Hope Medical Center
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	NCT00313586	Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Alkylating Agen... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult...	Azacitidine Entinostat Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant	NCT01812252	Chronic Myelomo... de Novo Myelody... Myelodysplastic... Secondary Myelo...	Azacitidine (AZ... Decitabine Quality-of-Life...	18 Years -	Fred Hutchinson Cancer Center
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	NCT00217646	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Blastic Phase de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Secondary Acute... Secondary Myelo...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	NCT00217646	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Blastic Phase de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Secondary Acute... Secondary Myelo...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome	NCT02553941	Chronic Myelomo... de Novo Myelody... Previously Trea... Refractory Anem... Secondary Myelo...	Azacitidine Ibrutinib	18 Years -	University of California, Davis
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	NCT02890329	Previously Trea... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... Secondary Acute... Secondary Myelo...	Decitabine Ipilimumab	18 Years -	National Cancer Institute (NCI)
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	NCT00101179	Acute Myeloid L... Chronic Myelomo... de Novo Myelody... Leukemia Myelodysplastic... Recurrent Adult... Secondary Acute... Secondary Myelo...	Azacitidine Entinostat	18 Years -	National Cancer Institute (NCI)
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia	NCT01757639	Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Previously Trea... Recurrent Adult... Secondary Myelo...	Ipilimumab Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome	NCT05379166	Secondary Myelo... Therapy-Related...	Azacitidine Quality-of-Life... Questionnaire A... Venetoclax	18 Years -	Ohio State University Comprehensive Cancer Center
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome	NCT03359460	Myelodysplastic... Previously Trea... Refractory High... Secondary Myelo... Therapy-Related...	Ibrutinib Lenalidomide	18 Years -	University of California, Davis

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: